Sakar Healthcare (SAKAR.NSE)

Sakar Healthcare share price today, ATLAS forecast and fair value

Healthcare · Drug Manufacturers - Specialty & Generic · National Stock Exchange of India · India

₹970.80▲ +9.10%

Prices as of Oct 26, 2026 · INR

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

48%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Sakar Healthcare in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Sakar Healthcare

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Sakar Healthcare a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between ₹873.66 and ₹1,062; in 9 out of 10, between ₹734.54 and ₹1,264. Estimated annual volatility is 60%.

Price, last 12 months (weekly close)

Key numbers

Market cap: ₹20.3B
Market cap (USD): $214M
P/E ratio: 67.1
52-week high: ₹1,230
52-week low: ₹352.05
Revenue (12 months): ₹2.7B
Operating margin: 20.2%
Net margin: 13.3%
Beta: 0.41

What this means

ATLAS does not publish a fair value for SAKAR.NSE right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks SAKAR.NSE has traded between ₹352.05 and ₹1,230. Today it is 21.1% below that high and 176% above its low.

On the business: net margin is 13.3%; it trades at 67.1 times earnings.

Its beta is 0.41: it tends to move less than the market.

About the company

Sakar Healthcare Ltd. is a prominent player in the pharmaceutical manufacturing industry. Primarily focused on producing a wide range of pharmaceutical products, this company offers its formulations in various dosage forms, including tablets, capsules, dry powder, and liquid injection.

Want to see everything about Sakar Healthcare?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Sakar Healthcare do?

What is the chance SAKAR.NSE goes up next month?

48%: close to a coin flip. In half of the simulated outcomes, SAKAR.NSE ends the month between ₹873.66 and ₹1,062.

How big is Sakar Healthcare and what is its P/E ratio?

Sakar Healthcare's market capitalization is ₹20.3B. Its price-to-earnings (P/E) ratio is 67.1: you pay ₹67.1 for each ₹1.00 of yearly earnings.

How volatile is SAKAR.NSE?

ATLAS estimates annual volatility at 60%. In a typical month, half of the outcomes end between ₹873.66 and ₹1,062.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer